ReviewAustralian prescriber2025
Aminoglycosides: an update on indications, dosing and monitoring.
Review in Australian prescriber, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Gentamicin Targeting Human Hemoglobin Induces Methemoglobin Formation and Decreases Oxygen Affinity: A Molecular Mechanism of Hematologic Toxicity.International journal of molecular sciences · 2026Article
- The Safety of Single Aminoglycoside Dose in Emergency Departments (SAD-ED) Among Patients With and Without Chronic Kidney Disease: A Retrospective Cohort Study.Emergency medicine Australasia : EMA · 2026Article
- Therapeutic drug monitoring of intravenous amikacin during peritoneal dialysis for Mycobacterium abscessus exit-site infection: a case report.Journal of pharmaceutical health care and sciences · 2026Article
- Therapeutic strategies for multi-resistantJAC-antimicrobial resistance · 2026Review
- Early clinical outcomes of routine prophylactic use of a gentamicin-impregnated sponge in all consecutive patients undergoing cardiac surgical operations: a single-center experience.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2026Article
- Effects of aminoglycosides on macrophage viability and antimicrobial function under high-glucose exposure.Scientific reports · 2026Article
- Antimicrobial Resistance inVeterinary sciences · 2026Article
- Mechanistic Evaluation of LolA andInternational journal of microbiology · 2026Article
- Aminoglycoside dosing and kidney function: which equation to use?Australian prescriber · 2025Article
- Recurrent urinary tract infection: Effect of glycemic status, disease severity and antimicrobial response in wasit, Iraq a prospective comparative cohort study.The journal of medicine accessArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aminoglycosides (gentamicin, tobramycin and amikacin) are highly effective parenteral drugs commonly used as initial empirical therapy of serious Gram-negative infections. They have rapid bactericidal activity and relatively low rates of resistance in Australia compared with other antibiotics used to manage Gram-negative infections. Therapeutic Guidelines: Antibiotic was updated in March 2025 and provides new guidance on the role of aminoglycosides, optimised dosing, and drug selection. The guidelines now recommend that dosing in adults is based on lean body weight, and provide calculators to assist with dose calculations. Therapeutic drug monitoring is required when aminoglycoside therapy is expected to continue beyond 48 hours; monitoring the area under the aminoglycoside concentration-time curve is recommended in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.